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Abstract
Background:  It has been generally well accepted that chronic inflammation is a necessary
component of lung fibrosis but this concept has recently been challenged.
Methods:  Using biochemical, histological, immunohistochemistry, and cellular analyses, we
compared the lung responses (inflammation and fibrosis) to fibrogenic silica particles (2.5 and 25
mg/g lung) in Sprague-Dawley rats and NMRI mice.
Results:  Rats treated with silica particles developed chronic and progressive inflammation
accompanied by an overproduction of TNF-α as well as an intense lung fibrosis. Dexamethasone
or pioglitazone limited the amplitude of the lung fibrotic reaction to silica in rats, supporting the
paradigm that inflammation drives lung fibrosis.
In striking contrast, in mice, silica induced only a limited and transient inflammation without TNF-
α overproduction. However, mice developed lung fibrosis of a similar intensity than rats. The
fibrotic response in mice was accompanied by a high expression of the anti-inflammatory and
fibrotic cytokine IL-10 by silica-activated lung macrophages. In mice, IL-10 was induced only by
fibrotic particles and significantly expressed in the lung of silica-sensitive but not silica-resistant
strains of mice. Anti-inflammatory treatments did not control lung fibrosis in mice.
Conclusion: These results indicate that, beside chronic lung inflammation, a pronounced anti-
inflammatory reaction may also contribute to the extension of silica-induced lung fibrosis and
represents an alternative pathway leading to lung fibrosis.
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Background
Lung fibrosis is often associated with an inflammatory
process which precedes or coexists with fibroblast prolif-
eration and deposition of extracellular matrix proteins [1].
Abundant human and experimental data have high-
lighted inflammation as a major effector in the develop-
ment of lung fibrosis [2-4]. Persistent inflammation
characterized by an accumulation of macrophages, neu-
trophils and lymphocytes in the lung causes the release of
degradative enzymes and oxidants capable of inducing
lung injury and DNA damage [5,6]. Lung inflammatory
cells are also a source of growth factors [7], cytokines [8]
and chemokines [9] that amplify and maintain alveolitis
and activate fibroblasts. It has been demonstrated, for
instance, that macrophages obtained from animal models
of silicosis [10] or from patients with lung fibrosis [11]
overproduce pro-inflammatory cytokines and growth fac-
tors such as TNF-α, IL-1, PDGF and TGF-β. All these medi-
ators clearly possess strong stimulating activities on
fibroblasts [4,12].
Beside this strong evidence of a major role of inflamma-
tion, other studies did not find a clear relationship
between lung inflammation and fibrosis and, thus, have
challenged this paradigm.
First, several studies, mainly conducted in mice, reported
that lung inflammation is not always followed by a
fibrotic disease. Adamson and colleagues showed that an
increased pulmonary inflammation induced by the leuko-
cyte chemoattractant FMLP (N-formyl-L-methionyl-leu-
cyl-phenylalanine), significantly reduced the fibrotic
response induced by silica in mice [13]. In addition, IL-10
deficient mice treated with silica showed an intense alve-
olitis but a reduced fibrotic lung response compared to
their wild-type counterparts [14]. Also, αvβ6 integrin
knockout mice developed marked lung inflammation in
response to bleomycin but failed to develop fibrosis [15].
Second, the control of inflammation is not always associ-
ated with a reduction of fibrosis. In mice, treatment with
anti-MIF (macrophage migration inhibitory factor) anti-
bodies significantly reduced the accumulation of inflam-
matory cells in the alveolar space as well as TNF-α
production after treatment with bleomycin but did not
affect the lung fibrotic response [16]. Also, IL-12p40-/-
mice treated with bleomycin exhibited reduced pulmo-
nary inflammation but increased fibrosis compared to the
wild type mice [17].
Finally, in humans, anti-inflammatory therapy has never
been definitely shown to significantly alter the course of
pulmonary fibrosis [18,19].
Collectively, these observations suggest that inflamma-
tion is not necessarily related to the fibrotic response and
that additional pathogenic routes can be responsible for
the development of a pulmonary fibrotic response. Alter-
native paradigms have therefore been proposed [20,21].
It has been postulated that pulmonary fibrosis may result
from sequential epithelial cell injury and abnormal
wound repair, independently from an inflammatory reac-
tion [22]. Angiogenesis may also constitute a pivotal proc-
ess in the development of lung fibrosis, independent of
lung inflammation [23]. We have recently proposed a
third pathogenic pathway which is based on the profi-
brotic activity of anti-inflammatory cytokines such as IL-
4, IL-13, TGF-β but also IL-10 [24]. Indeed, these
cytokines stimulate, directly or indirectly, the fibroblasts
to proliferate and/or to produce extracellular matrix pro-
teins. Their protracted overproduction in the lung, e.g. in
response to a sustained insult, may in turn drive a fibrotic
process.
In this study, we compared the lung responses to silica in
Sprague-Dawley rats and NMRI mice, two animal models
largely used to study the pathogenesis of lung fibrosis
[25,26]. By comparing these species, we show that the
extension (rats) but also the control of the inflammatory
reaction (mice) induced by silica particles may both lead
to the emergence of similar fibrotic lesions.
Methods
Animals
Female NMRI mice and Sprague-Dawley rats weighing
respectively 20 to 25 g and 200 to 300 g, were purchased
from Charles River (Brussels, Belgium). Female BALB/c,
C57BL/6J, and DBA2 mice were obtained from our local
breeding facility (Ludwig Institute, Brussels). The animals
were housed in positive pressure air-conditioned units
(25°C, 50% relative humidity) on a 12-hr light/dark
cycle. The experimental protocol was approved by the
local committee for animal use at the Université
catholique de Louvain.
Instillation method
To allow sterilization and inactivation of any trace of
endotoxin, particles were heated at 200°C for 2 h imme-
diately before suspension and administration.
A suspension of crystalline silica particles (DQ12; d50 =
2.2 µm, a gift from Dr L. Armbruster Essen, Germany) in
sterile 0.9% saline was injected directly into the lungs of
mice and rats by intratracheal instillation. To allow a com-
parison between both species, the doses of silica were
adjusted to administer 2.5 and 25 mg of silica per g of
lung (lung weight; mouse about 200 mg and rat about 1.2
g; ratio = 6; instillation of 0.5 or 5 mg silica in 60 µl ofRespiratory Research 2005, 6:112 http://respiratory-research.com/content/6/1/112
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saline in mice and 3 or 30 mg silica in 360 µl saline in
rats). These doses of silica are comparable to those usually
used in the literature to induce intense lung fibrosis
[27,28]. All instillations were performed on anesthetized
animals after surgical opening of the neck. Two mg of
sodium pentobarbital (Certa, Braine-l'Alleud, Belgium) or
a mix of 10 mg of Ketalar (N.V. Warner-Lambert, Zaven-
tem, Belgium) and 2 mg of Rompun (Bayer A6, Leverkus-
sen, Germany) were used to anesthetize rats or mice,
respectively.
For the particle comparative model, 2.5 mg of silica, tung-
sten carbide (WC, d50 = 1 µm) or manganese dioxide
(MnO2, d50 = 3.7 µm) particles in sterile 0.9% saline (60
µl) were injected directly into the lungs of mice by intrat-
racheal instillation.
Bronchoalveolar lavage and whole lung homogenates
At selected time intervals after silica treatment (3, 30 and
60 days), mice and rats were sacrificed with sodium
pentobarbital (20 mg/mice and 120 mg/rat, i.p) and a
bronchoalveolar lavage (BAL) was performed by cannu-
lating the trachea and infusing the lungs twice with sterile
0.9 % saline. The volume of saline used for BAL was deter-
mined on the basis of the lung weight (ratio between rat
and mouse weight = 6). Since mice are usually lavaged
with 1 ml, we used 6 ml for lavaging the rats. BAL fluid
fractions were centrifuged (1500 rpm, 10 min, 4°C) and
the cell-free supernatant of the first fraction was used for
biochemical measurements. The cell pellets of the two
BALF fractions were pooled and resuspended with 2 ml of
sterile saline for mice and 12 ml for rats. Aliquots of the
cell suspensions were used to determine cell numbers
(200 cells counted). Cell differentials were performed on
cytocentrifuge preparations fixed in methanol and stained
with Diff-Quik (Baxter, Lessines, Belgium).
Separately, at day 3, 30 or 60 after treatment, non-lavaged
whole lungs were perfused and excised. The right lobes
were placed into a Falcon tube chilled on ice and 3 ml
(mice) or 18 ml (rats) of cold 0.9% NaCl were added. The
content of each tube was then homogenized with a Ultra-
Turrax T25 homogenizer (Janke and Kunkel, Brussels, Bel-
gium) during 30 second. The homogenates were kept fro-
zen at -80°C until use.
The time points analyzed in this study were selected to
correspond to the peaks of inflammation (3 days) and
fibrosis (2 months) in the mouse and rat models
[25,29,28].
Biochemical analyses
Lactate dehydrogenase (LDH) activity in BALF was
assayed spectrophotometrically by monitoring the reduc-
tion of nicotinamide adenine dinucleotide (NAD+) at 340
nm in the presence of lactate. Total proteins in BALF were
determined by the pyrogallol red staining method (Tech-
nicon RA system; Bayer Diagnostics, Domont, France).
Silica measurement
The amount of silica particles remaining in the lungs of
rats and mice was measured after 3, 30 and 60 days fol-
lowing administration. The concentration of silica was
determined colorimetrically with the molybdenum blue
method after digestion in sodium hypochlorite [30].
Anti-inflammatory therapy
Dexamethasone (2.5 µg/ml) was administered in the
drinking water starting 3 days before silica (25 mg/ g lung)
or saline instillation both in rats (0.25 mg/kg/d) and mice
(0.375 mg/kg/d). Two times per week throughout the
experimental protocol, 1.25 mg of dexamethasone phos-
phate (Sigma) was diluted to 500 ml of drinking water
[31]. Pioglitazone (Takeda, Japan, commercialized by Eli
Lilly, Belgium) was added to powdered standard rodent
chow (0.01% wt/wt, ad libitum) [32]. This treatment
started 3 days before silica or saline pulmonary adminis-
tration (10 and 15 mg/kg/d in rats and mice, respectively).
Control animals were given powdered standard lab chow
ad libitum and tap water. The selection of dose of anti-
inflammatory molecules were based on those reported in
the literature to significantly attenuate inflammation in
rats and mice [31,33,34,32]. Two months after silica or
saline treatment, animals were sacrificed and BALF
inflammatory parameters (see above) as well as lung col-
lagen deposition (see below) were quantified.
Collagen assay
Collagen deposition was estimated by measuring the lung
hydroxyproline content. Lung homogenates were hydro-
lyzed in 6N HCl overnight at 110°C. Hydroxyproline was
assessed by high- performance liquid chromatography
analysis [35] and data are expressed as micrograms of
hydroxyproline per ml of lung homogenate.
Enzyme-linked immunosorbent assays (ELISA)
Type I collagen contents were measured in lung homoge-
nate supernatants (5000 rpm, 4°C, for 10 min) using
standardized ELISA as previously described [36].
Mouse and rat IL-10 (Biosource International, Camarillo,
CA, USA), TNF-α (Pharmingen, BD Biosciences, San
Diego, USA) concentrations were measured in lung and
BAL supernatants using ELISA kits following the manufac-
turer's protocols. The detection limits of these ELISA are
respectively 0.9, 5, 5 and 5 (pg/ml).
Histopathology and immunohistochemical staining
The left lung of silica-treated or control mice was excised
and fixed in Bouin solution (Merck-Belgolabo, Belgium).Respiratory Research 2005, 6:112 http://respiratory-research.com/content/6/1/112
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Lactate dehydrogenase (LDH) activity, total protein content and neutrophil numbers in bronchoalveolar lavage of Sprague- Dawley (SD) rats (A-C) and NMRI mice (D-F) after intratracheal instillation of saline or silica particles (2.5 or 25 mg/ g lung) Figure 1
Lactate dehydrogenase (LDH) activity, total protein content and neutrophil numbers in bronchoalveolar lavage of Sprague-
Dawley (SD) rats (A-C) and NMRI mice (D-F) after intratracheal instillation of saline or silica particles (2.5 or 25 mg/ g lung). 
Bars represent means +/- SEM of 5 to 7 animals. Significant differences between treated animals and controls: *P < 0.05, **P < 
0.01, ***P < 0.001 (Student-Newman-Keuls multiple comparison test). Please note the different scales between mice and rats 
for LDH and neutrophils.
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Paraffin-embedded sections were stained with hematoxy-
lin and eosin or Masson's trichrome for light microscopic
examination. For immunohistochemistry stainings,
dewaxed and rehydrated tissue sections were subjected to
endogenous peroxidase inactivation (0.5% H2O2 for 20
min) followed by three washes of 5 minutes in PGT buffer
(phosphate-buffered saline [PBS], 0.05% Tween 20, and
0.02% gelatine). An incubation was then performed for 1
h in a humidified room with a rat monoclonal anti-mouse
IL-10 antibody (SXC1) diluted 250 times in PBS. After 3
washes with PGT buffer (5 min each), tissue sections were
exposed for 1 h to the second antibody (polyclonal rabbit
against rat IgG coupled with peroxidase as second anti-
body, Dako, Copenhagen, Denmark) diluted 40-fold in
PBS supplemented with 1% mouse serum. Tissue sections
were then rinsed and washed three times in PGT buffer.
The peroxidase activity was revealed by 3-3'-diaminoben-
zidine tetrahydrochloride (Aldrich, Beerse, Belgium)-
H2O2 substrate. The staining was enhanced by incubation
in a solution of 0.5% CuSO4 in saline for 15 min. Sections
were counterstained with Harris hematoxylin, rinsed,
dehydrated, and mounted in DPX (BDH, Poole, UK).
Statistics
Treatment-related differences were evaluated using t tests
and one-way analysis of variance, followed by pairwise
comparisons using the Student-Newman-Keuls test, as
appropriate. Statistical significance was considered at P <
0.05.
Results
Pulmonary inflammation induced by silica particles was 
persistent in rats but limited in mice
LDH activity, protein levels and neutrophil numbers
measured in BALF were used to estimate the amplitude of
pulmonary inflammation induced by silica particles both
in rats and mice (2.5 and 25 mg/g of lung) (Figure 1). At
all time points and in a dose-dependent manner, silica
induced a significant increase in BALF LDH and protein
levels in rats (Figure 1 A &1 B). Similarly, an accumulation
of lung neutrophils (Figure 1 C), macrophages and lym-
phocytes (data not shown) was observed in silica-treated
rats in a dose-related manner. These effects were progres-
sive and the most pronounced 30 and 60 days after parti-
cle treatment. Thus, these observations showed the
establishment of a chronic alveolitis in silica-treated rats.
In mice, BALF LDH and protein levels were found
increased only at day 3 after silica treatment and both
parameters had returned to control values after 60 days. A
dose-dependent recruitment of pulmonary neutrophils
was noted at day 3 in the BALF of silica-treated mice but
this neutrophil accumulation did not last after 30 days.
The modifications of BALF numbers of macrophages and
lymphocytes were similar to that observed with neu-
trophils (data not shown). On the basis of these results,
we concluded that mice controlled silica-induced alveoli-
tis and did not develop chronic inflammation.
Rats and mice developed a similar lung fibrotic reaction to 
silica
To estimate silica-induced lung fibrosis, hydroxyproline
and type-1 collagen levels were measured in lung
homogenates in both species. A clear accumulation of
extracellular matrix components was noted both in rats
and mice after 60 days (Figure 2). The amplitude of the
lung fibrotic reaction was relatively similar in both species
since, at the highest dose tested, silica induced a 2.9- and
2.1-fold increase in OH-proline, in rats and mice respec-
tively (Figure 2 A &2 C). Type-1 collagen contents were
2.2- and 3-fold increased in silica-treated rats and mice,
respectively (Figure 2 B &2 D). As shown in Figure 3, both
species developed clear silicotic lesions characterized by
the formation of well defined and organized silicotic nod-
ules. No significant lung fibrosis was noted at days 3 and
30 in the two silica-treated species (data not shown).
These results indicated therefore that, while rats and mice
treated with equivalent doses of silica developed contrast-
ing inflammatory responses, both species showed in turn
similar lung fibrotic reactions.
The lung persistence of silica particles was similar in rats 
and mice
The amplitude of silica-induced lung inflammation and
fibrosis directly depends on the amount of particles
retained in the lung. We therefore assessed the amount of
silica particles that remained in the lungs in both species.
Similar amounts of silica particles were retrieved 30 and
60 days after treatment in both rats and mice (day 30,
respectively 96.9 ± 9.8 and 80.4 ± 24.9 percent of the
mean silica content measured 3 days, values represent
means ± SEM; day 60, respectively 113.1 ± 22.6 and 110.3
± 28.5 %; n = 5 to 7). On the basis of these data, we
excluded a difference in the clearance of silica particles to
explain the varying lung responses between rats and mice.
The lung response to silica was characterized by the 
production of pro-inflammatory mediators (TNF-α) in rats 
and of anti-inflammatory mediators (IL-10) in mice
It is well demonstrated that pro-inflammatory cytokines
such as TNF-α are involved in the pathogenesis of silica-
induced lung disease [12]. TNF-α levels were therefore
measured in BALF and lung homogenates of rats and mice
treated with silica (Figure 4 A–C). A dose-dependent and
progressive increase of TNF-α in BALF was observed after
silica treatment in rats (Figure 4 A). Similar data were
obtained by measuring TNF-α in lung homogenates by
ELISA or by assessing the amounts of TNF-α transcripts
(semi-quantitative RT-PCR) in BALF cells and whole lungsRespiratory Research 2005, 6:112 http://respiratory-research.com/content/6/1/112
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(data not shown). In striking contrast, no such induction
was found in BALF (Figure 4 C) or lung homogenates
(data not shown) of silica-treated mice. Since it is well
demonstrated that the anti-inflammatory cytokine IL-10
may downregulate the expression of TNF-α, we assessed
IL-10 levels in the BALF and lung homogenates of silica-
treated rats and mice (Figure 4 B–D). A significant and
dose-dependent increase of IL-10 production was
observed in lung homogenates of silica-treated mice at
day 60 (Figure 4 D). No similar IL-10 induction was noted
Hydroxyproline and type 1 collagen contents in lung homogenates of SD rats (A-B) and NMRI mice (C-D) 60 days after intrat- racheal instillation of saline or silica particles (2.5 or 25 mg/ g lung) Figure 2
Hydroxyproline and type 1 collagen contents in lung homogenates of SD rats (A-B) and NMRI mice (C-D) 60 days after intrat-
racheal instillation of saline or silica particles (2.5 or 25 mg/ g lung). Bars represent means +/- SEM of 5 to 7 animals. Significant 
differences between treated animals and controls: *P < 0.05, **P < 0.01, ***P < 0.001 (Student-Newman-Keuls multiple com-
parison test).
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in treated rats (Figure 4 B). Moreover, it was noteworthy
that the basal IL-10 content (saline) was 20-fold higher in
the lung of mice than in rats (at day 3, saline rats: 175.5 ±
1.2 vs saline mice: 3618.1 ± 422.8 pg/ml). IL-10 was not
detected in BALF neither in rats nor in mice. The differ-
ences in IL-10 expression were confirmed by semi-quanti-
tative RT-PCR in BALF cells and lung homogenates (data
not shown). No similar effect on the levels of IL-4, IL-13
or IFN-γ was noted in this model. Altogether, these results
indicated that the mediators associated to the lung
response to silica were opposite in both species. The rat
lung response was characterized by the expression of a
pro-inflammatory cytokine such as TNF-α while the
mouse lung response involved an anti-inflammatory
cytokine such as IL-10. These observations also suggested
that the limited lung inflammation observed in mice
could be related, at least in part, to their increased expres-
sion of IL-10.
IL-10 expression was intimately related to silica-induced 
lung fibrosis in mice
In order to further explore the role of IL-10 in the estab-
lishment of lung fibrosis in mice, we used a mouse model
that allows a comparison among three different types of
particles (tungsten carbide, WC; manganese dioxide,
MnO2; and crystalline silica, SiO2) and the identification
of specific events leading to the extension of lung fibrosis
[37]. After intratracheal instillation of these mineral dusts,
the pulmonary responses in NMRI mice were character-
ized respectively by no inflammation (NI), resolutive
alveolitis (RA) or fibrosing alveolitis (FA). As already
observed, a persisting increase of IL-10 production was
observed in the FA model (silica) which paralleled the
establishment of lung fibrosis (Figure 5 A). No significant
change in lung IL-10 content was noted in the saline, NI
(poorly soluble particles of low toxicity, WC) or RA
(inflammatory but not fibrogenic particles) groups, indi-
cating that IL-10 induction in mice seems specific to the
fibrotic process. No similar effect on the levels of IL-4, IL-
13 or IFN-γ was noted in this comparative model.
To determine the localization and cellular sources of IL-10
in the fibrotic model (FA), we evaluated lung tissue sec-
tions obtained at the late stage of the disease (120 days).
This analysis showed that, in silica-treated mice, alveolar
macrophages appeared as the major cells expressing IL-10.
The corresponding sections showed no staining with con-
trol non-immune IgG (data not shown). Using polarized
light and high magnification, we found that mainly mac-
rophages that had phagocytozed silica particles expressed
IL-10 (Figure 5 B).
To complete the data obtained in mice, we also deter-
mined the IL-10 levels in the lung of several strains of
mice presenting different sensitivities to silica [38]. BALB/
c, C57BL/6J and DBA2 mice received silica particles (2.5
mg/mouse) or saline. Two months after treatment,
collagen deposition and histology were assessed to moni-
tor the lung fibrotic response. As previously described
[38], we observed that DBA2 mice developed the most
severe fibrotic lesions. While C57BL/6 mice developed
intermediate lung fibrosis, BALB/c mice responded
weakly to silica. This gradient of susceptibility was illus-
trated by measuring pulmonary collagen contents and by
histological analysis (data not shown). Lung IL-10 levels
were related to the amplitude of pulmonary fibrosis.
Indeed, IL-10 contents were significantly higher after silica
treatment in lung homogenates of DBA2 mice in compar-
ison to their respective controls (Figure 5 C). While no dif-
ference between saline- and silica-treated groups was
noted in C57BL/6, in BALB/c mice silica treatment
Representative silicotic nodules from (A) SD rats and (B)  NMRI mice 60 days after silica instillation (25 mg/g lung) Figure 3
Representative silicotic nodules from (A) SD rats and (B) 
NMRI mice 60 days after silica instillation (25 mg/g lung). 
Masson trichrome staining. Magnification 200X.
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induced a reduction of IL-10 contents in comparison to
saline (Figure 5 C). Levels of IL-10 in lung tissue of saline
mice were as follows: BALB/c = 605 ± 36; C57BL/6 = 683
± 62 and DBA/2 = 1049 ± 123 pg/lung. No similar effect
on the levels of IL-4, IL-13 or IFN-γ was noted in this com-
parative model.
Altogether, we concluded that expression of IL-10 was
intimately correlated with the amplitude of silica-induced
lung fibrosis.
Levels of TNF-α in BALF and IL-10 in lung homogenates of SD rats (A-B) and NMRI mice (C-D) after intratracheal instillation  of saline or silica particles (2.5 or 25 mg/ g lung) Figure 4
Levels of TNF-α in BALF and IL-10 in lung homogenates of SD rats (A-B) and NMRI mice (C-D) after intratracheal instillation 
of saline or silica particles (2.5 or 25 mg/ g lung). Bars represent means +/- SEM of 5 to 7 animals. Significant differences 
between treated animals and controls: **P < 0.01, ***P < 0.001 (Student-Newman-Keuls multiple comparison test). At day 3, 
absolute levels of TNF-α in saline rats and mice were respectively 6.3 ± 0.7 and 11.7 ± 1.2 pg/ml. For IL10, 175.5 ± 1.2 and 
3618.1 ± 422.8 pg/ml were respectively detected in saline rats and mice (day 3).
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Reduction of inflammation prevented silica-induced lung 
fibrosis in rats but not in mice
Our observations suggested two opposite lung responses
in association with the development of silica-induced
lung fibrosis (inflammatory and anti-inflammatory,
respectively in rats and mice). In order to delineate the
role of lung inflammation in both models of lung fibrosis,
we treated silica-administered rats and mice with anti-
inflammatory molecules. Dexamethasone (corticoster-
oids) and pioglitazone (a peroxisome proliferator-acti-
vated receptor-gamma agonist) were used in this study
because they have been shown to control lung inflamma-
tion [33,34]. In rats, silica-induced lung fibrosis was sig-
nificantly reduced both after dexamethasone or
pioglitazone treatment as estimated by OH-proline or
type I collagen lung levels (Figure 6 A and 6 B). This reduc-
tion of lung fibrosis was accompanied by a limited accu-
mulation of leukocytes in the lung but not by an
amelioration of biochemical parameters (i.e., LDH and
protein BALF levels; at day 60) (data not shown). In strik-
ing contrast, the anti-inflammatory treatments had no
similar effect on the amplitude of lung fibrosis in silica-
treated mice. Moreover, pioglitazone administration
increased the pulmonary levels of OH-proline and type I
collagen after silica (Figure 6 C and 6 D), denoting an
exacerbated lung fibrotic process in this group. No signif-
icant effect of the anti-inflammatory treatments was
observed on lung inflammatory parameters as well as
cytokine production (IL-10, IL-4, IL-13 and IFN-γ) in
mice. Altogether, these data indicated that the inflamma-
tory process drives the pathogenesis of lung fibrosis in rats
but not in mice.
Discussion
Lung fibrosis, in humans as well as in experimental mod-
els, is often associated with pulmonary inflammation
characterized by the accumulation of macrophages, lym-
phocytes and granulocytes [1]. These inflammatory cells
release toxic oxygen derivatives and proteolytic enzymes
which cause cellular damage and disruption of the extra-
cellular matrix which, in turn, leads to destroying lung
architecture [39]. Inflammatory cells are also considered
to be a major source of mediators such as cytokines and
growth factors, which possess the ability to stimulate
fibroblast functions critical to fibrogenesis [1].
This scenario was largely described in models of lung
fibrosis induced by silica or asbestos mainly in rats [40].
Indeed, compelling evidence demonstrates that pro-
inflammatory cytokines such as IL-1 and TNF-α not only
regulate chronic lung inflammation but also fibrosis. For
instance, activated alveolar macrophages purified from
rats instilled with silica particles release pro-inflammatory
mediators such as IL-1 and TNF-α as well as MIP-2,
responsible for the persistence of inflammation and the
A: Time-dependent IL-10 production in the lung of NMRI  mice in the fibrosing alveolitis (FA), resolving alveolitis (RA)  and non-inflammatory models (NI) Figure 5
A: Time-dependent IL-10 production in the lung of NMRI 
mice in the fibrosing alveolitis (FA), resolving alveolitis (RA) 
and non-inflammatory models (NI). Bars represent means +/- 
SEM of 5 to 6 animals. Significant differences from controls: 
*P < 0.05 (Student-Newman-Keuls multiple comparison 
test). B: Cellular immuno-localization of IL-10 production in 
the FA model at day 120. Mainly macrophages having phago-
cytozed silica particles expressed IL-10. C: IL-10 contents in 
lung homogenates of BALBc, C57BL/6 and DBA/2 mice 60 
days after intratracheal instillation of silica (2.5 mg). DBA2 
mice developed the most severe fibrotic lesions and 
expressed the highest IL-10 levels. The results for individual 
mice are shown. The bars denote the mean values for each 
group (n = 8 to 9). Significantly different from controls: *P < 
0.05 (Student-Newman-Keuls multiple comparison test).
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development of fibrosis [10,41]. The fact that lung inflam-
mation and production of pro-inflammatory cytokines
leads to the development of fibrosis was also reported in
models using bleomycin or ionizing radiation to induce
lung fibrosis [12,42]. In the present study, we also found
that Sprague-Dawley rats injected with silica particles
developed progressive inflammation, with a dramatic
accumulation of neutrophils at the latter stage of the dis-
ease. As already demonstrated [10,29], the lung response
to silica in rats was accompanied by an overproduction of
TNF-α. The key role of the inflammatory reaction in the
extension of lung fibrosis induced by silica was demon-
strated by the efficacy of anti-inflammatory therapy in this
study. Indeed, in rats, silica-induced fibrosis was strongly
attenuated by dexamethasone or pioglitazone administra-
tion (Figure 6).
By contrast, in the mouse model used in this study, the
lung response to silica was not associated with chronic
inflammation or a significant up-regulation of TNF-α
Hydroxyproline and type 1 collagen contents in lung homogenates of SD rats (A-B) and NMRI mice (C-D) 60 days after intrat- racheal instillation of saline or silica particles (2.5 or 25 mg/ g lung) and after dexamethasone or pioglitazone treatment Figure 6
Hydroxyproline and type 1 collagen contents in lung homogenates of SD rats (A-B) and NMRI mice (C-D) 60 days after intrat-
racheal instillation of saline or silica particles (2.5 or 25 mg/ g lung) and after dexamethasone or pioglitazone treatment. Bars 
represent means +/- SEM of 5 to 7 animals. Significant differences between treated animals and controls: *P < 0.05, **P < 0.01, 
***P < 0.001 (Student-Newman-Keuls multiple comparison test).
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expression. This control of inflammation in mice was
accompanied by a pronounced expression of IL-10, both
at the basal level as well as in response to silica. The fact
that this marked overproduction of IL-10 in the lung may
contribute to limit inflammation induced by silica is
largely supported by existing experimental studies. In
mice genetically deficient in IL-10, we have previously
reported that the administration of silica particles induced
an enhanced inflammatory reaction compared to wild
type animals [14]. Furthermore, IL-10 has been shown to
suppress tissue inflammation in other mouse models of
lung insult induced by Pneumocystis Carinii infection
[43], endotoxin [44], bleomycin [45] or immune com-
plexes [46]. The absence of response to anti-inflammatory
drugs in mice further supports the fact that fibrosis was
not driven by inflammation in this species.
Our data indicate that despite its anti-inflammatory prop-
erties, IL-10 participates to the extension of the fibrotic
reaction. An obvious association between the extent of IL-
10 overexpression and the amplitude of fibrosis was
shown in this study. First, alveolar macrophages, strongly
implicated in the pathogenesis of lung fibrosis induced by
silica particles [47], were identified as the main cellular
source of IL-10 in mice (Figure 5 B). Moreover, using sev-
eral mineral particles inducing different lung responses,
we showed that IL-10 production in the lung of mice was
up-regulated during the development of fibrosing alveoli-
tis (FA, silica) but not in the resolutive alveolitis (RA,
MnO2) or the non-inflammatory models (NI, WC) (Fig-
ure 5 A). In addition, IL-10 was up-regulated in silica-sus-
ceptible mice (DBA2) but reduced in a resistant strain
(BALB/c) (Figure 5 C). It is noteworthy that these last
characteristics recapitulate those reported for the pro-
fibrotic and pro-inflammatory cytokine TNF-α in the rats.
Indeed, TNF-α is overproduced mainly by activated lung
macrophages, induced in the rat lung only by fibrotic par-
ticles [10], and overexpressed in silica-treated sensitive
animals [48,27]. Together with our previous observations
demonstrating a pro-fibrotic activity of IL-10 in the lung
of mice treated with silica particles [14,24,49], we can
conclude that the overexpression of IL-10 documented in
the lung of mice in the present study contributed to the
establishment of the fibrotic response.
The mechanism by which IL-10 exerts its pro-fibrotic
effect is still unclear. The possibility that IL-10 may
directly stimulate fibroblasts has already been tested with
conflicting results. Thus, Liu and colleagues showed that
IL-10 had no significant effect on human fetal lung fibrob-
lasts [50]. In contrast, it has been reported that IL-10
might downregulate type I procollagen mRNA expression
in skin fibroblasts [51], as well as constitutive and TGF-β-
stimulated type I collagen mRNA expression in a human
lung fibroblast cell line [45]. By using primary cultures of
mouse lung fibroblasts, we previously showed that unlike
other Th2 cytokines such as IL-4 and IL-13 [52,53], IL-10
did not directly modulate fibrosis-associated functions,
such as proliferation and collagen or α-SMA expression
[24]. IL-10 could, however, exert its pro-fibrotic action by
up-modulating the expression of pro-fibrotic mediators
such as TGF-β. Indeed, in IL-10 transgenic mice, the
expression of TGF-β was found increased in the lung [54],
which is consistent with our previous study showing a sig-
nificant reduction of TGF-β lung levels in IL-10 deficient
mice exposed to silica [24]. Moreover, IL-10 enhances the
expression of the type II TGF-β receptor and restores TGF-
β responsiveness on activated T cells [55] but similar
effects have not been explored in fibroblasts. Recent work
from this laboratory showed that, in mice treated with sil-
ica, lung overexpression of IL-10 upregulated the produc-
tion of other Th2 cytokines such as IL-4 and IL-13. Since
there is evidence that pulmonary fibrosis is a Th2-medi-
ated process, we speculate that elevated lung levels of IL-
10 may also contribute to the progression of fibrosis via
its capacity to stimulate Th2 polarized responses. Collec-
tively, these observations strongly indicate that IL-10, an
anti-inflammatory/Th2 cytokine, exacerbates the severity
and pathology of lung fibrosis, at least in the mouse.
Conclusion
On the basis of the comparative models studied here, we
suggest that at least two different types of lung response to
silica can lead to the development of lung fibrosis. First, as
observed in the Sprague-Dawley rats, lung fibrosis is the
consequence of a chronic and exaggerated inflammatory
response associated with an overproduction of pro-
inflammatory mediators also possessing pro-fibrotic
activities such as TNF-α. In mice, marked expression of
anti-inflammatory cytokines such as IL-10 have beneficial
effects by limiting and controlling inflammation. How-
ever, in this species, because of its pro-fibrotic properties,
IL-10 participates to the extension of fibrosis. Thus, in
mice, the strong anti-inflammatory response established
to control inflammation could contribute to the fibrotic
reaction induced by silica. These data clearly suggest that
several pathogenic routes are responsible for the develop-
ment of a pulmonary fibrotic response.
It remains however, to learn how to extrapolate these
observations to human diseases. Anti-inflammatory ther-
apies used in this study had no effect on lung fibrosis in
mice while they were very efficient in the control of the
disease in rats. This may indicate that the treatment of pul-
monary fibrosis may need to be modulated according to
the type of pathogenic mechanism involved.
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